Royce & Associates LP Increases Stock Holdings in Pediatrix Medical Group, Inc. $MD

Royce & Associates LP boosted its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 42.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 254,748 shares of the company’s stock after purchasing an additional 75,702 shares during the quarter. Royce & Associates LP owned approximately 0.30% of Pediatrix Medical Group worth $5,449,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Clearstead Advisors LLC raised its holdings in Pediatrix Medical Group by 733.7% in the fourth quarter. Clearstead Advisors LLC now owns 3,368 shares of the company’s stock worth $72,000 after purchasing an additional 2,964 shares in the last quarter. LSV Asset Management raised its holdings in Pediatrix Medical Group by 51.1% in the fourth quarter. LSV Asset Management now owns 462,200 shares of the company’s stock worth $9,886,000 after purchasing an additional 156,400 shares in the last quarter. Global Retirement Partners LLC raised its holdings in Pediatrix Medical Group by 68,250.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock worth $29,000 after purchasing an additional 1,365 shares in the last quarter. ProShare Advisors LLC raised its holdings in Pediatrix Medical Group by 4.6% in the fourth quarter. ProShare Advisors LLC now owns 16,816 shares of the company’s stock worth $360,000 after purchasing an additional 734 shares in the last quarter. Finally, TD Private Client Wealth LLC bought a new position in Pediatrix Medical Group in the fourth quarter worth $39,000. Institutional investors own 97.71% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Friday, March 27th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a report on Friday, February 20th. UBS Group lifted their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Finally, Mizuho set a $24.00 price objective on Pediatrix Medical Group in a report on Friday, May 8th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $22.50.

Insider Activity

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Price Performance

NYSE MD opened at $21.54 on Friday. The business’s fifty day moving average price is $21.98 and its 200-day moving average price is $21.73. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of 10.46 and a beta of 0.70. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. On average, equities analysts predict that Pediatrix Medical Group, Inc. will post 2.08 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.